New study highlights Arcoxia's effectiveness for fasting headaches; Should Life Technologies go private?;

@FierceBiotech: Stem cells from ear can create new cartilage. News | Follow @FierceBiotech

@JohnCFierce: Wondering if the dread "Dendreon effect" will alter any biotech's future marketing plans for cancer drugs. Leave it to the experts? | Follow @JohnCFierce

@RyanMFierce: U.S.'s brand as 'land of opportunity' is in jeopardy, I think. China biotech entrepreneur's quote says it all. Article | Follow @RyanMFierce

@MaureenFierce: Genzyme VP: Rare-disease drug developers in it for 'long-haul.' Story | Follow @MaureenFierce

> A new study indicates that Arcoxia, a pain drug closely resembling Vioxx that proved too risky for U.S. regulators to approve, may be an effective treatment for the headaches induced by religious fasting. A large number of Muslims who fast during Ramadan complain of headaches. Piece

> Jon Groberg at Macquarie Equities Research is making the case that Life Technologies, which makes scientific equipment, should go private. More

> One of Boehringer Ingelheim's units is getting out of the contract manufacturing business. Story

Pharma News

@FiercePharma: Another cancer-drug rejection for NICE: Watchdog says AstraZeneca's Faslodex doesn't beat current therapy. News | Follow @FiercePharma

> As drug prices grow, payers dig into patients' wallets. News

> 'More bang for buck' from GSK's Cervarix. Details

> NICE nixes AZ's Faslodex in prelim guidance. Story

> Sanofi in talks to buy Indian OTC business. Report

Biotech Research News

> At last, a cause found for Lou Gehrig's disease. News

> Researchers build against body's natural defense against C. difficile. Article

> Stem cells from ears can create new cartilage. More

> A recipe for drug variation: Just add sugar. Story

> Stem cells to heart parts in 5 years, researchers say. Details

Manufacturing News

> WHO sends Panacea to remediation. More

> Meth makers to be foiled by jelly. Story

> Lilly, Genentech bolster QA functions. News

> Takeda parlays Baxter's vax methods into Japanese subsidies. Details

> Turbulence ahead for cancer drugs with Ben Venue exit. Report

> Sagent's vecuronium launch a hope against drug shortages. Article

And Finally... An international team of researchers say they have successfully created the first computerized genome-scale model of cancer cell metabolism, which can be used to predict which drugs are lethal to a cancer cell's metabolism. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.